Literature DB >> 17588222

Silencing of the type 1 insulin-like growth factor receptor increases the sensitivity to apoptosis and inhibits invasion in human lung adenocarcinoma A549 cells.

Zhiyuan Ma1, Aiqiang Dong, Minjian Kong, Jianfang Qian.   

Abstract

The type 1 insulin-like growth factor receptor (IGF-1R), which is over-expressed or activated in many human cancers, including lung cancer, mediates cancer cell proliferation and metastasis. Several studies indicate that blocking IGF-1R expression can inhibit tumor cell proliferation and metastasis. In this study, inhibition of the endogenous IGF-1R by recombinant adenoviruses encoding short hairpin RNAs against IGF-1R was found to significantly suppress IGF-1R expression, arrest the cell cycle, enhance the apoptotic response, and inhibit proliferation, adhesion, invasion and migration in A549 cells. Moreover, silencing IGF-1R decreases the expression of invasive-related genes including matrix metalloproteinase-2 (MMP-2), MMP-9, and urokinase-plasminogen activator (u-PA), and the phosphorylation of Akt and ERK1/2. These results suggest that the silencing of IGF-1R has the potential to be an effective cancer gene therapy strategy for human lung cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17588222      PMCID: PMC6275632          DOI: 10.2478/s11658-007-0022-1

Source DB:  PubMed          Journal:  Cell Mol Biol Lett        ISSN: 1425-8153            Impact factor:   5.787


  42 in total

1.  Overexpression of the human insulinlike growth factor I receptor promotes ligand-dependent neoplastic transformation.

Authors:  M Kaleko; W J Rutter; A D Miller
Journal:  Mol Cell Biol       Date:  1990-02       Impact factor: 4.272

2.  Induction of tumor suppression and glandular differentiation of A549 lung carcinoma cells by dominant-negative IGF-I receptor.

Authors:  Y Jiang; W N Rom; T A Yie; C X Chi; K M Tchou-Wong
Journal:  Oncogene       Date:  1999-10-28       Impact factor: 9.867

3.  RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.

Authors:  Sai MuraliKrishna Pulukuri; Christopher S Gondi; Sajani S Lakka; Aman Jutla; Norman Estes; Meena Gujrati; Jasti S Rao
Journal:  J Biol Chem       Date:  2005-08-26       Impact factor: 5.157

4.  Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells.

Authors:  Katia Scotlandi; Cecilia Maini; Maria Cristina Manara; Stefania Benini; Massimo Serra; Vanessa Cerisano; Rosaria Strammiello; Nicola Baldini; Pier-Luigi Lollini; Patrizia Nanni; Giordano Nicoletti; Piero Picci
Journal:  Cancer Gene Ther       Date:  2002-03       Impact factor: 5.987

5.  Activation of the insulin-like growth factor-I receptor inhibits tumor necrosis factor-induced cell death.

Authors:  Y Wu; M Tewari; S Cui; R Rubin
Journal:  J Cell Physiol       Date:  1996-09       Impact factor: 6.384

6.  Genetic blockade of the insulin-like growth factor-I receptor: a promising strategy for human pancreatic cancer.

Authors:  Yongfen Min; Yasushi Adachi; Hiroyuki Yamamoto; Hideto Ito; Fumio Itoh; Choon-Taek Lee; Sorena Nadaf; David P Carbone; Kohzoh Imai
Journal:  Cancer Res       Date:  2003-10-01       Impact factor: 12.701

7.  Dual regulation of MMP-2 expression by the type 1 insulin-like growth factor receptor: the phosphatidylinositol 3-kinase/Akt and Raf/ERK pathways transmit opposing signals.

Authors:  Donglei Zhang; Menashe Bar-Eli; Sylvain Meloche; Pnina Brodt
Journal:  J Biol Chem       Date:  2004-03-01       Impact factor: 5.157

8.  Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity.

Authors:  Mariana Salatino; Roxana Schillaci; Cecilia J Proietti; Romina Carnevale; Isabel Frahm; Alfredo A Molinolo; Adolfo Iribarren; Eduardo H Charreau; Patricia V Elizalde
Journal:  Oncogene       Date:  2004-07-01       Impact factor: 9.867

9.  Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro.

Authors:  Y Nakanishi; J L Mulshine; P G Kasprzyk; R B Natale; R Maneckjee; I Avis; A M Treston; A F Gazdar; J D Minna; F Cuttitta
Journal:  J Clin Invest       Date:  1988-07       Impact factor: 14.808

10.  Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice.

Authors:  K Scotlandi; S Benini; P Nanni; P L Lollini; G Nicoletti; L Landuzzi; M Serra; M C Manara; P Picci; N Baldini
Journal:  Cancer Res       Date:  1998-09-15       Impact factor: 12.701

View more
  10 in total

1.  Insulin-like growth factor-1 receptor-targeted therapy for non-small cell lung cancer: a mini review.

Authors:  Ming Yin; Xiaoxiang Guan; Zhongxin Liao; Qingyi Wei
Journal:  Am J Transl Res       Date:  2009-01-30       Impact factor: 4.060

2.  Lentivirus-mediated RNAi knockdown of insulin-like growth factor-1 receptor inhibits growth, reduces invasion, and enhances radiosensitivity in human osteosarcoma cells.

Authors:  Yin-He Wang; Zhao-Xia Wang; Yong Qiu; Jin Xiong; Yi-Xin Chen; Deng-Shun Miao; Wei De
Journal:  Mol Cell Biochem       Date:  2009-02-20       Impact factor: 3.396

3.  The IGF-I receptor can alter the matrix metalloproteinase repertoire of tumor cells through transcriptional regulation of PKC-{alpha}.

Authors:  Shun Li; Donglei Zhang; Long Yang; Julia V Burnier; Ni Wang; Rongtuan Lin; Eunice R Lee; Robert I Glazer; Pnina Brodt
Journal:  Mol Endocrinol       Date:  2009-10-23

Review 4.  Personalized therapy of sarcomas: integration of biomarkers for improved diagnosis, prognosis, and therapy selection.

Authors:  Joseph A Ludwig
Journal:  Curr Oncol Rep       Date:  2008-07       Impact factor: 5.075

5.  TROP2 is epigenetically inactivated and modulates IGF-1R signalling in lung adenocarcinoma.

Authors:  Jau-Chen Lin; Yi-Ying Wu; Jing-Yi Wu; Tzu-Chieh Lin; Chen-Tu Wu; Yih-Leong Chang; Yuh-Shan Jou; Tse-Ming Hong; Pan-Chyr Yang
Journal:  EMBO Mol Med       Date:  2012-03-15       Impact factor: 12.137

6.  Klotho inhibits growth and promotes apoptosis in human lung cancer cell line A549.

Authors:  Bo Chen; Xueli Wang; Weihong Zhao; Jianqing Wu
Journal:  J Exp Clin Cancer Res       Date:  2010-07-19

7.  IGF1R signaling in Ewing sarcoma is shaped by clathrin-/caveolin-dependent endocytosis.

Authors:  Ana Sofia Martins; José Luis Ordóñez; Ana Teresa Amaral; Frans Prins; Giuseppe Floris; Maria Debiec-Rychter; Pancras C W Hogendoorn; Enrique de Alava
Journal:  PLoS One       Date:  2011-05-17       Impact factor: 3.240

8.  BMS-754807 is cytotoxic to non-small cell lung cancer cells and enhances the effects of platinum chemotherapeutics in the human lung cancer cell line A549.

Authors:  S Elizabeth Franks; Robert A Jones; Ritesh Briah; Payton Murray; Roger A Moorehead
Journal:  BMC Res Notes       Date:  2016-03-01

9.  Dual targeting of the insulin-like growth factor and collateral pathways in cancer: combating drug resistance.

Authors:  Joseph A Ludwig; Salah-Eddine Lamhamedi-Cherradi; Ho-Young Lee; Aung Naing; Robert Benjamin
Journal:  Cancers (Basel)       Date:  2011-07-26       Impact factor: 6.639

10.  The novel hsa-miR-12528 regulates tumourigenesis and metastasis through hypo-phosphorylation of AKT cascade by targeting IGF-1R in human lung cancer.

Authors:  Seong Ho Jeon; Jung Ki Yoo; Chang Min Kim; Eun Su Lim; So Jeong Lee; Ji Min Lee; Seung-Hun Oh; Jin Kyeoung Kim
Journal:  Cell Death Dis       Date:  2018-05-01       Impact factor: 8.469

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.